

From: [redacted]@mscbs.es
Sent: vendredi 30 octobre 2020 19:03
To: SANTE C3 HSC
Cc: [redacted].es; [redacted]@aemps.es; [redacted]@mscbs.es
Subject: RE: COVID-19 Vaccine Effectiveness Studies EU
Attachments: COVID-19 Vaccine Effectiveness Studies EU_final_SPAIN.docx

Dear HSC Secretariat,

Please, find attached the document with the Spanish answers (in red) to the three proposed questions.

Best regards

[redacted]
HSC Member
SPAIN

De: SANTE-C3-HSC@ec.europa.eu [<mailto:SANTE-C3-Hxx@xx.xxxxxpa.eu>]
Enviado el: jueves, 29 de octubre de 2020 10:19
Para: SANTE-C3-HSC@ec.europa.eu
Asunto: FW: COVID-19 Vaccine Effectiveness Studies EU

Dear members of the Health Security Committee,
Dear colleagues,

We are sending this kind reminder to the countries which have not sent us their replies yet, please, to the below questions.

Thank you very much.

Kind regards,

HSC Secretariat

De : SANTE-C3-HSC@ec.europa.eu <SANTE-C3-HSC@ec.europa.eu>
Envoyé : vendredi 23 octobre 2020 11:00
À : SANTE-C3-HSC@ec.europa.eu
Objet : COVID-19 Vaccine Effectiveness Studies EU
Importance : Haute

Dear Members of the Health Security Committee,

As you are aware, a large portfolio of COVID-19 vaccine candidates is being selected to accelerate their development, manufacturing and deployment. Once authorised, safety and the effectiveness of vaccines should be monitored.

The ECDC and EMA, in collaboration with the EC, Member States (NITAGs) and other partners are planning enhanced vaccine effectiveness, coverage, safety and impact monitoring activities specifically for COVID-19 vaccines.

We are sending you today a background paper with 3 questions about such post-marketing authorization studies. We plan to discuss this issue in the Health Security Committee.

Please reply to the questions by Friday 30 Oct 2020.

Kind regards,

HSC Secretariat

Questions to the Health Security Committee:

1. Is your country planning national / sub-national studies to monitor the safety and effectiveness of (a) COVID-19 vaccine(s), once available?
2. If yes, what kind of study/studies are you planning and what will you monitor?
 - a. Vaccination coverage
 - b. Vaccine acceptance
 - c. Safety
 - d. Effectiveness
 - e. Immunogenicity
 - f. Other things
3. Are you interested to participate in multi-country studies that would be coordinated by ECDC and EMA?

Les ministères sociaux agissent pour un développement durable.

Préservons l'environnement : n'imprimons que si nécessaire !

CONFIDENCIALIDAD. El contenido de este mensaje y el de cualquier documentación anexa es confidencial y va dirigido únicamente al destinatario del mismo. Si Usted no es el destinatario, le solicitamos que nos lo indique, no comunique su contenido a terceros y proceda a su destrucción.

CONFIDENTIALITY. The content of this message and any attached information is confidential and exclusively for

the use of the addresser. If you are not the addresser, we ask you to notify to the sender, do not pass its content and delete the original.